Federal Register / Vol. 75, No. 108 / Monday, June 7, 2010 / Notices 32185 

the mitochondrial PTEN-induced 

kinase-1 (PINK1), accumulates on the 

surface on damaged mitochondria, and 

that the presence of full-length PINK1 is 

necessary and sufficient for Parkin 

recruitment to the mitochondria. Thus, 

both Parkin and PINK1 play specific 

and important roles in mitochondrial 

quality control and disposal. 

This technology describes methods of 

treating Parkinson’s disease or other 

mitochondrial diseases such as KSS 

(Kearns Sayre syndrome), MERRF 

(Myoclonus epilepsy ragged-red fibers), 

MELAS (mitochondrial 

encephalomyopathy, lactic acidosis and 

stroke-like episodes), NARP 

(Neuropathy ataxia, retinitis 

pigmentosa), and LHON (Leber 

hereditary optic neuropathy) by 

increasing PINK1 or Parkin expression 

or activity, as well as methods of 

reducing the number of defective 

mitochondria in a cell by increasing 

PINK1 or Parkin expression or activity. 

Applications: 

• Development of therapies for 

Parkinson’s disease and other diseases 

associated with mitochondrial 

dysfunction. 

• Development of individualized 

treatment regimens for mitochondrial 

diseases through ex vivo or in vitro 

testing of candidate drugs. 

Inventors: Richard J. Youle et al. 

(NINDS). 

Related Publications: 

1. A Abeliovich. Parkinson’s disease: 

Mitochondrial damage control. News 

and Views, Nature 2010 Feb 

11:463:744–745. [PubMed: 20148026]. 

2. D Narendra et al. PINK1 is 

selectively stabilized on impaired 

mitochondria to activate Parkin. PLoS 

Biol. 2010 Jan 26;8(1):e1000298. 

[PubMed: 20126261]. 

3. D Narendra et al. Parkin-induced 

mitophagy in the pathogenesis of 

Parkinson disease. Autophagy. 2009 

Jul;5(5):706–708. [PubMed: 19377297]. 

4. D Narendra et al. Parkin is recruited 

selectively to impaired mitochondria 

and promotes their autophagy. J Cell 

Biol. 2008 Dec 1;183(5):795–803. 

[PubMed: 19029340]. 

Patent Status: U.S. Provisional 

Application No. 61/256,601 filed 30 Oct 

2009 (HHS Reference No. E–225–2009/ 

0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Tara Kirby, PhD; 

301–435–4426; tarak@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Neurological 

Disorders and Stroke is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize methods of treating 

mitochondrial diseases by increasing 

PINK1 or Parkin expression or activity. 

Please contact Dr. Martha Lubet at 301– 

435–3120 or lubetm@mail.nih.gov for 

more information. 

A Highly Sensitive ELISA for Detection 

of Serum Levels of Soluble IL-15 

Receptor Alpha 

Description of Invention: The 

invention is an ELISA based assay that 

can be used in the clinical setting to 

detect the presence of soluble human IL15 receptor (IL-15R) in the serum or 

plasma. 

Interleukin-15 (IL-15), a cytokine has 

potential as an immunotherapeutic 

agent for cancer treatment because it is 

a critical factor for the proliferation and 

activation of natural killer (NK) and 

CD8+ T-cells. 

In addition to studies directed toward 

augmenting IL-15 action to increase 

patient immune responses to their 

tumor, IL-15R alpha play a pathogenic 

role in leukemia and autoimmune 

disorders. IL-15 and IL-15R alpha are 

coexpressed in association with a 

number of autoimmune disorders 

including rheumatoid arthritis, 

psoriasis, inflammatory bowel disease, 

multiple sclerosis, chronic liver disease, 

and refractory celiac syndrome 

including that disease associated with 

the development of enteropathy 

associated CD8 T-cell lymphoma. An 

assay for the released serum form of IL15R alpha is required to evaluate these 

IL-15R alpha inducing agents. 

Applications: 

• The assay has the potential of being 

a commercial assay for clinical use to 

detect soluble human IL-15R alpha (sIL15R alpha) in serum or plasma. 

• The assay will help in predicting 

the efficacy of IL-15-based therapies 

since high levels of IL-15R are thought 

to be necessary to optimize the 

therapeutic effects of IL-15. 

• The assay can be used to identify 

patients who can be good candidates for 

IL-15 therapy. 

• The assay may also help clinicians 

identify patients susceptible to diseases 

associated with disorders of IL-15R 

expression. 

Advantages: 

• The assay is in the industry 

accepted ELISA format. 

• This non-radioactive ELISA assay 

has a sensitivity of 1pg/ml that is 

significantly more sensitive than the 

current industry detection level of 20 

pg/ml. 

Development Status: Developed at the 

proof-of concept level and laboratory 

setting. Clinical validation of the assay 

is currently being planned. 

Market: The assay can be used in the 

clinical setting to detect very low levels 

of IL-15R alpha in the serum or plasma 

of patients. 

IL-15R alpha disorders have been 

demonstrated in leukemia and 

autoimmune disorders such as 

rheumatoid arthritis, multiple sclerosis, 

celiac disease, and psoriasis as well as 

those with disorders associated with the 

retrovirus, HTLV-I. Additionally, select 

lymphomas express IL-15R alpha. 

Inventors: Thomas A. Waldmann and 

Jing Chen (NCI). 

Related Publication: Waldmann TA. 

The biology of interleukin-2 and 

interleukin-15: Implications for cancer 

therapy and vaccine design. Nat Rev 

Immunol. 2006 Aug;6(8):595–601. 

[PubMed: 16868550]. 

Patent Status: 

• U.S. Provisional Application No. 

61/241,265 filed 10 Sep 2009 (HHS 

Reference No. E–079–2009/0–US–01). 

• U.S. Provisional Application No. 

61/242,595 filed 10 Sep 2009 (HHS 

Reference No. E–079–2009/1–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Sabarni Chatterjee, 

PhD; 301–435–5587; 

chatterjeesa@mail.nih.gov. 

Collaborative Research Opportunity: 

The Center for Cancer Research, 

Metabolism Branch, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize this technology. Please 

contact John Hewes, PhD at 301–435– 

3131 or hewesj@mail.nih.gov for more 

information. 

Dated: June 1, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–13606 Filed 6–4–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

32186 Federal Register / Vol. 75, No. 108 / Monday, June 7, 2010 / Notices 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Software System for Analysis of 

Extremely Large Experimental Dataset 

and Multidimensional Drug Discovery 

Description of Invention: This 

invention is a computer software suite 

that will enable its user to investigate 

extremely large experimental datasets in 

a simple yet multidimensional manner. 

The software, Omnimorph, allows 

multidimensional investigation of any 

form of data including experimental 

datasets in biomedical science using 

either gene arrays or proteomics. 

Omnimorph allows the user to look for 

extremely subtle correlated differences 

between experimental datasets which 

will allow the investigator to discover 

far more drug- or disease-specific factors 

than other analytical methods currently 

used. The software of present invention 

has been employed in the targeted 

discovery of G protein-independent 

receptor-based pharmacotherapeutics. 

These discoveries represent an entirely 

new GPCR-based G protein-independent 

pharmacopeia. Therefore, the 

Omnimorph is not only newly 

developed software, but the Omnimorph 

suite can also be used as a simple and 

unbiased tool to detect novel and 

unexpected modes of GPCR-based drug 

actions. This could potentially alter the 

way drugs are developed and screened 

in the future. 

Applications: 

• Development and screen for 

pharmaceutical drugs. 

• Biomedical research. 

Development Status: 

• The invention has been fully 

developed. 

• The software will be readily 

available if so requested. 

Inventors: Stuart R. Maudsley et al. 

(NIA). 

Patent Status: HHS Reference No. E– 

143–2010/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for 

licensing. 

Licensing Contacts: Uri Reichman, 

PhD, MBA; 301–435–4616; 

UR7a@nih.gov; or Michael Shmilovich, 

Esq.; 301–435–5019; 

ShmilovichM@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute on Aging, 

Laboratory of Neurosciences-Receptor 

Pharmacology Unit, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize this technology. Please 

contact John Hewes, PhD at 301–435– 

3131 or hewesj@mail.nih.gov for more 

information. 

Sound Attenuation Canopy for 

Reducing Noise Transmitted Through 

Suspended Ceilings 

Description of Invention: Available for 

licensing and commercial 

implementation in commercial facilities 

design and construction are intellectual 

property rights covering a sound 

attenuation canopy for reducing noise 

transmitted through suspended ceiling 

systems commonly used in most office 

buildings. The canopy is designed to 

absorb sound energy and effectively 

reduce the direct path of sound 

travelling within open plenum 

suspended ceilings like those used in 

most office building environments. The 

canopy can also act as an umbrella to 

shield loose debris and dust which may 

be located in the plenum and 

potentially fall when ceiling suspended 

return-air grilles are moved or accessed. 

The canopy has an added benefit of 

reducing heating or cooling loss which 

may naturally ventilate through the 

return air plenum grille from a 

conditioned office space below. Also, 

the canopy controls leakage of heating 

and cooling, reducing loads on the 

central building systems thereby 

lessening energy costs and extending 

the life-cycle of the building’s physical 

plant. 

The canopy does not impede natural 

air flow for ventilating the plenum 

cavity but deters the spread of smoke or 

fire between the plenum and the office 

space below. The canopy can also act as 

a secondary air balancer or K Factor 

balancer to equate supply and return air 

to control room temperature. The 

canopy is pliable and therefore allows 

for ease of adjustment within varying 

plenum conditions as well as readily 

installed in ceiling plenums. 

Applications: 

• Building design and construction. 

• Sound attenuation. 

• Energy load reduction. 

Inventors: Judit A. Quasney, Franklin 

Koh, John P. Jenkins, Robert M. 

Alexander, Daniel P. O’Brien (NIAID). 

Patent Status: U.S. Patent Application 

No. 12/764,872 filed 21 Apr 2010 (HHS 

Reference No. E–102–2010/0–US–01) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Dated: June 1, 2010. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2010–13597 Filed 6–4–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Task Force on Community Preventive 

Services 

Name: Task Force on Community 

Preventive Services meeting. 

Times and Dates: 8 a.m.–5:30 p.m. 

EST, June 16, 2010. 8 a.m.–1 p.m. EST, 

June, 17, 2010. 

Place: Centers for Disease Control and 

Prevention, 2500 Century Center, 

Atlanta, GA 30329. 

Status: Open to the public, limited 

only by space available. 

Purpose: The mission of the Task 

Force is to develop and publish the 

Guide to Community Preventive 

Services (Community Guide), which is 

based on the best available scientific 

evidence and current expertise 

regarding essential public health and 

what works in the delivery of those 

services. 

Matters to be discussed: (1) Updates 

of prior reviews on the following topics: 

Reducing Vaccine-Preventable Diseases; 

Increasing Screening for Breast, 

Cervical, and Colorectal Cancer. 

(2) New reviews on: Immunization 

Information Systems; Collaborative Care 

for the Management of Depressive 

Disorders and Communication 

Campaigns with Product Distribution. 

Agenda items are subject to change as 

priorities dictate. 

Contact person or additional 

information: Freda Parker, Community 

Guide Branch, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road, M/S E–69, Atlanta, GA 30333, 

phone: 404.498.1119. 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES